

## DESCRIPTION

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human VEGF in direct ELISAs and Western blots. In direct ELISAs, approximately 100% cross-reactivity with recombinant canine VEGF is observed, and less than 20% cross-reactivity with recombinant mouse VEGF <sub>165</sub> and recombinant rat VEGF <sub>164</sub> is observed, and less than 5% cross-reactivity with recombinant zebrafish VEGF is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant human VEGF <sub>165</sub> Ala27-Arg191 Accession # NP_001165097.1
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.


## APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	5-10 µg/mL	See Below
<b>Immunocytochemistry</b>	5-15 µg/mL	See Below
<b>Immunohistochemistry</b>	3-15 µg/mL	See Below
<b>Neutralization</b>	Measured by its ability to neutralize VEGF <sub>165</sub> -induced proliferation in HUVEC human umbilical vein endothelial cells. Conn, G. <i>et al.</i> (1990) Proc. Natl. Acad. Sci. USA <b>87</b> :1323. The Neutralization Dose (ND <sub>50</sub> ) is typically 0.02-0.12 µg/mL in the presence of 10 ng/mL Recombinant Human VEGF <sub>165</sub> .	


## DATA

### Western Blot




**Detection of Human VEGF by Western Blot.** Western blot shows lysates of human lung tissue, human kidney tissue, and human liver tissue. PVDF membrane was probed with 5-10 µg/mL of Goat Anti-Human VEGF<sub>165</sub> Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for VEGF at approximately 27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

### Immunocytochemistry




**VEGF in HUVEC Cells.** VEGF was detected in immersion fixed human umbilical vein endothelial cells (HUVECs) using Goat Anti-Human VEGF<sub>165</sub> Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (yellow; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

### Immunohistochemistry



**VEGF in Human Liver Cancer Tissue.** VEGF was detected in immersion fixed paraffin-embedded sections of human liver cancer tissue using Goat Anti-Human VEGF<sub>165</sub> Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

### Neutralization



**Cell Proliferation Induced by VEGF<sub>165</sub> and Neutralization by Human VEGF Antibody.** Recombinant Human VEGF<sub>165</sub> (Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human VEGF<sub>165</sub> (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human VEGF<sub>165</sub> Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA). The ND<sub>50</sub> is typically 0.02-0.12 µg/mL.

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"><li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li><li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li><li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li></ul>

## BACKGROUND

Vascular Endothelial Growth Factor (VEGF or VEGF-A), also known as Vascular Permeability Factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure. VEGF<sub>165</sub> appears to be the most abundant and potent isoform, followed by VEGF<sub>121</sub> and VEGF<sub>189</sub>. Human VEGF<sub>165</sub> is an approximately 44 kDa molecular weight homodimer sharing 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells. Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity. VEGF<sub>165</sub> binds the Semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2. VEGF is required during embryogenesis and functions to regulate the proliferation, migration, and survival of endothelial cells. In adults, VEGF functions mainly in wound healing and the female reproductive cycle. Pathologically, it is involved in tumor angiogenesis and vascular leakage. Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, Oncostatin M (OSM) and TNF-alpha.